Endocrine Abstracts

Introduction: Pregnancy for women with Graves’ disease is at risk for the mother and the newborn. In fact neonatal hyperthyroidism is uncommon, often transient in the context of maternal Graves’ disease (1% of children). Immediate treatment is essential for a good prognosis, prenatal treatment improves foetal and neonatal development.

Case report: We report the case of a patient, known for Graves’ disease since 2006, treated initially with carbimazole for 18 months.She was in remission for 2 years, but in December 2013 as she relapse, she was treated by radio-iodine (one month before conception). She gave birth to a premature 31 SA, in 21 August 2014 with subclinical hyperthyroidism (TSH: 0.07 UI/ml and FT₄: 7.09 pg/ml). After 15 days the new born present an overt hyperthyroidism (TSH: 0.01 UI/ml and FT₄: 23.5 pg/ml) with TSI: 6.89 UI/l. The baby receives carbimazole for 2 months and became euthyroid.

Conclusion: Neonatal hyperthyroidism should be screened in all newborn from mother with Graves’ disease treated by radical treatment (radio-iodine or thyroidectomy) because TSI freely cross the placental barrier and thus stimulate the thyroid of the newborn. Prognosis of neonatal hyperthyroidism mediated by anti maternal body is quite good as they disappear in 4–12 weeks after birth.